Syntimmune, Inc., a Newton, MA- and New York, NY-based clinical-stage biotechnology company, raised the latest $8m tranche of its $26m Series A financing.
Investors include Apple Tree Partners, Baxalta Ventures, and Partners Innovation Fund.
Founded in 2013 by Dr. Laurence Blumberg, Chief Operating Officer, and led by new President and Chief Executive Officer David de Graaf, Ph.D., Syntimmune is advancing novel therapies for IgG-mediated autoimmune diseases based the biology of the neonatal Fc receptor (FcRn). Its lead candidate, SYNT001, is a biologic that specifically blocks FcRn-IgG interactions and is advancing into multiple 1b/2a trials for the treatment of IgG-mediated autoimmune diseases. In addition to SYNT001, the company is developing two, earlier-stage therapeutic programs targeting other unique aspects of FcRn biology.
The company, which has raised $28m in total capital to date, intends to use the funds to advance its Phase 1b/2a studies.